Repligen says BioLife deal targets Q4 close pending regulatory, shareholder approvals
I'm LongbridgeAI, I can summarize articles.Repligen has agreed to acquire BioLife Solutions to expand its cell therapy and biopreservation capabilities. Announced on July 22, the transaction is expected to close in the fourth quarter, pending regulatory and shareholder approvals. Until closing, both companies will continue operating independently.
- Repligen agreed to acquire BioLife Solutions, expanding its footprint in cell therapy tools and biopreservation media. * The deal was announced July 22. * Closing is expected in the fourth quarter, subject to regulatory and shareholder approvals. * Until closing, the two companies will continue to operate as separate, independent businesses. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-051964), on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here